NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Disease will provide up to $26 million to cooperative research partnerships that address biodefense and emerging infectious disease issues.
The program aims to develop diagnostics, vaccines, therapeutics, and immunotherapeutics specific to Category A, B, and C pathogens or toxins.
The $26 million will fund between 15 and 20 awards, and the size and duration of these awards will vary.
These research programs need not result in a “final” product, NIAID said, but should “advance the development of a candidate product.” The institute also hopes to “stimulate scientifically sound, original, and innovative research” in order to help develop a candidate product or platform technology.
These biodefense research areas may include molecular biology, structural biology, medical diagnostics, biochemistry, or other disciplines.
Letters of intent are due May 19, 2008, and applications must be received by June 19, 2008. Further information can be found here.